Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Proteomic markers enhance mortality prediction in heart failure.

European heart journal·2026

Same author

Country-specific differences in the association between obesity risk factors in two high-income countries: a cross-sectional analysis from the Prospective Urban Rural Epidemiology (PURE) study.

BMC public health·2026

Same author

Real-world outcomes from 2,905 episodes of hospital at home care: a propensity-matched cohort study.

Frontiers in digital health·2026

Same author

Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study.

Breast cancer research and treatment·2026

Same author

Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement.

JAMA oncology·2025

Same author

Efficacy and cardiovascular safety of liposomal doxorubicin: a systematic review and meta-analysis of randomized trials.

Cardio-oncology (London, England)·2025

Search research articles

Related Experiment Video

Updated: May 15, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Right ventricular function and survival following cardiac resynchronisation therapy.

Darryl P Leong¹, Ulas Höke, Victoria Delgado

¹Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.

Heart (British Cardiac Society)

|January 15, 2013

Summary

Right ventricular (RV) function is a key predictor of mortality in heart failure patients undergoing cardiac resynchronisation therapy (CRT). Improved RV function after CRT is linked to better survival outcomes.

More Related Videos

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Published on: June 15, 2020

Related Experiment Videos

Last Updated: May 15, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Published on: June 15, 2020

Area of Science:

Cardiology
Heart Failure Research
Echocardiography

Background:

Right ventricular (RV) function is a critical prognostic indicator in heart failure.
The independent impact of RV function on mortality after cardiac resynchronisation therapy (CRT) remains unclear.
Limited data exists on how CRT affects RV function.

Purpose of the Study:

To determine the prognostic significance of RV function in patients receiving CRT.
To characterize changes in RV function post-CRT and identify influencing factors.

Main Methods:

Retrospective observational study at a single tertiary centre.
Echocardiographic assessment of RV function (TAPSE) in 848 CRT recipients before and 6 months after therapy.
Primary endpoint: long-term all-cause mortality.

Main Results:

Baseline RV dysfunction was present in 34% of patients.
Reduced RV function (TAPSE) independently predicted higher all-cause mortality.
Improvement in RV function post-CRT was associated with better survival and linked to LV diastolic function improvement.

Conclusions:

Right ventricular function is an independent predictor of long-term outcomes in CRT recipients.
Assessing RV function provides crucial prognostic information beyond established parameters.